Jim Simons Chembio Diagnostics, Inc. Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.25 - $0.45 $5,175 - $9,315	20,700 Added 15.18%	157,100 $69,000
Q4 2022 Feb 13, 2023	BUY	$0.2 - $0.33 $4,560 - $7,524	22,800 Added 20.07%	136,400 $30,000
Q3 2022 Nov 14, 2022	BUY	$0.35 - $1.1 $31,534 - $99,110	90,100 Added 383.4%	113,600 $41,000
Q2 2022 Aug 12, 2022	BUY	$0.45 - $0.8 $10,575 - $18,800	23,500 New	23,500 $15,000
Q3 2021 Nov 12, 2021	SELL	$2.06 - $5.34 $112,216 - $290,891	-54,474 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$2.88 - $5.64 $288,478 - $564,936	-100,166 Reduced 64.77%	54,474 $162,000
Q1 2021 May 13, 2021	BUY	$3.4 - $7.97 $525,776 - $1.23 Million	154,640 New	154,640 $543,000
Q3 2019 Nov 13, 2019	SELL	$4.84 - $7.25 $166,980 - $250,125	-34,500 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$5.56 - $7.85 $199,048 - $281,030	-35,800 Reduced 50.92%	34,500 $210,000
Q1 2019 May 14, 2019	SELL	$5.32 - $7.18 $74,474 - $100,512	-13,999 Reduced 16.61%	70,300 $390,000
Q4 2018 Feb 13, 2019	BUY	$4.95 - $10.5 $417,280 - $885,139	84,299 New	84,299 $477,000

Ticker CEMI
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,224,600
Description
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, la...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.